Abstract Library

#4666 Merkel cell neuroendocrine carcinoma of the skin: High response rates to short course palliative radiotherapy – Typical clinical scenarios

Introduction: Merkel cell carcinomas (MCC) are a rare, aggressive skin neuroendocrine carcinomas, with peak incidence in the elderly. MCC often presents as a firm, red/purple painless nodule with a short history of increasing size. Surgery is considered the 1st line treatment but elderly patients, in particular, have comorbidities which may preclude radical surgery requiring reconstruction. In advanced MCC, immunotherapy (IO) is 1st line systemic treatment. Chemotherapy is used 2nd line or if contraindications for IO but can be challenging in an elderly population. There may be an emerging role for PRRT due to the presence of somatostatin receptors on MCC. Radiotherapy (RT) can be used for non-surgical candidates, or those with unresectable or metastatic disease. Adjuvant post-operative irradiation (PORT) may provide additional benefit in risk reduction and improves local control.

Conference:

Presenting Author:

Authors: Saunders E, Sizer B, Collins J, Skelly R, Srinivasan G,

Keywords: Merkel cell, skin, radiotherapy,

#4101 Pulmonary neuroendocrine tumors – Symptomatology, tumor characteristics, treatment strategies, and long-term outcomes in 37 Patients

Introduction: Pulmonary Neuroendocrine Tumors (NET) constitute a complex group of diseases with varied clinical manifestations and no definitive diagnostic and treatment guidelines.

Conference:

Presenting Author: Krishna B

Authors: Jain D, Eshpuniyani P, Deshpande R, Sharma S, Krishna B,

Keywords: epidemiology, pulmonary NET, lobectomy, prognosis,

#3054 Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumour: Nutrition in NETs Study

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP NET) can adversely affect nutritional status. Cross-sectional studies report up to 25% of GEP NET patients are malnourished and dietary change may be prevalent. Nevertheless, clinical guidelines lack advice on nutrition management.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Laing E

Authors: Laing E, Kiss N, Michael M, Krishnasamy M, Gough K,

Keywords: neuroendocrine, nutrition, malnutrition, weight change, symptoms,

#1410 Predictive Factors for Survival in Patients with Advanced Small Bowel Neuroendocrine Tumours

Introduction: Tumour grade and hepatic metastases are negative prognostic factors for advanced small bowel neuroendocrine tumours (SBNETs), but data assessing other prognosticators at diagnosis (Dx) are lacking.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: TOUMPANAKIS C

Authors: Toumpanakis C, Vlachou E, Ramakrishnan S, Phillips E, Tuck A,

Keywords: small bowel NETs, prognosis,

#1239 Histological Classification of Pancreatic Neuroendocrine Tumours: Optimising the Ki67 System

Introduction: Pancreatic neuroendocrine tumours are graded using the Ki67 antigen in accordance with the WHO 2010 classification. Despite the system’s widespread use, a wide variety of tumour behaviours have been described leading to various proposed revisions.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Mills L, Ramage J, Prachalias A, Srinivasan P, Menon K,

Keywords: G3,